Investor Moves
| Investor | Portfolio Value | Portfolio Change | Position Change | Avg Buy Price | Current Price |
|---|---|---|---|---|---|
Ken GriffinCitadel Advisors $-6.1M ExitQ1 2026 $6.1M -- $15.52 | |||||
Paul Tudor Jones IITudor Investment $2.7M152.6k shares AddQ1 2026 $529k $17.84 $15.52 | |||||
Ken GriffinCitadel Advisors $6.1M462.8k shares AddQ4 2025 $4.8M $13.08 $15.52 | |||||
Jim SimonsRenaissance Technologies $-711.3K ExitQ4 2025 $711k -- $15.52 | |||||
News
globenewswire.comTelitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in Chinaglobenewswire.comJun 8
globenewswire.comTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in Chinaglobenewswire.comJun 8
globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 1
globenewswire.comVor Bio to Participate in the 2026 Jefferies Global Healthcare Conferenceglobenewswire.comMay 28
globenewswire.comVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicineglobenewswire.comMay 14